Sun Juxian, Liu Chang, Wang Nanya, Jiang Dafeng, Zhang Fan, Shi Jie, Cheng Shuqun
Department of Hepatic Surgery VIa, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, People's Republic of China.
Department of Oncology, First Hospital of Jilin University, Changchun, People's Republic of China.
Cancer Manag Res. 2022 May 5;14:1663-1670. doi: 10.2147/CMAR.S354170. eCollection 2022.
To study the impact of All-trans-retinoic acid (ATRA) plus FOLFOX4 compared to FOLFOX4 alone in patients with advanced hepatocellular carcinoma (HCC) with pulmonary metastasis.
The data of patients with advanced HCC who underwent systemic chemotherapy using FOLFOX4 or ATRA plus FOLFOX4 at the Eastern Hepatobiliary Surgery Hospital, First Hospital of Jilin University, Zhejiang Sian International Hospital and Fujian Cancer Hospital were retrospectively analyzed. The survival outcomes in the 2 groups were compared.
From May 2014 to July 2020, 66 patients were suitable to enter into this study. The median survival (14.0 vs 8.0 months, p=0.012), and the median time to progression in the ATRA plus FOLFOX4 group were both significantly longer than those in the FOLFOX4 group (8.7 vs 3.2 months, p=0.002). The 6 month-, 1 year- and 2 year- overall survival rates were also significantly better in the ATRA plus FOLFOX4 group (100.0%, 64.7% and 20.5%; respectively) than the FOLFOX4 group (59.4%, 21.9%, and 12.5%, respectively; p<0.001). Leukocytopenia, fatigue, anorexia, nausea, were the most common acute toxicities, but these were mostly NCI CTCAE Grade 1 or 2. There was no significant difference in adverse events between the two groups.
ATRA plus FOLFOX4 significantly improved the survival outcomes in patients with advanced HCC with pulmonary metastasis.
研究全反式维甲酸（ATRA）联合FOLFOX4方案与单纯FOLFOX4方案相比，对晚期肝细胞癌（HCC）肺转移患者的影响。
回顾性分析在东方肝胆外科医院、吉林大学第一医院、浙江新安国际医院和福建省肿瘤医院接受FOLFOX4或ATRA联合FOLFOX4全身化疗的晚期HCC患者的数据。比较两组的生存结局。
2014年5月至2020年7月，66例患者适合纳入本研究。ATRA联合FOLFOX4组的中位生存期（14.0个月对8.0个月，p = 0.012）和中位疾病进展时间均显著长于FOLFOX4组（8.7个月对3.2个月，p = 0.002）。ATRA联合FOLFOX4组的6个月、1年和2年总生存率也显著优于FOLFOX4组（分别为100.0%、64.7%和20.5%）（分别为59.4%、21.9%和12.5%；p<0.001）。白细胞减少、疲劳、厌食、恶心是最常见的急性毒性反应，但大多为美国国立癌症研究所不良事件通用术语标准（NCI CTCAE）1级或2级。两组不良事件无显著差异。
ATRA联合FOLFOX4显著改善了晚期HCC肺转移患者的生存结局。
